In brief, the HER2 peptide vaccine may not alleviate the medical conditions of HER2/neu-high-expressing patients, as their immune system has been defective in responses to high HER/neu expression, and therefore, tolerate the survival and growth of cancer cells. The gene discussed is ERBB2; the disease is cancer.